J&J, Boston U partner to map early detection biomarkers for lung cancer

The Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University unveiled a five-year collaboration to identify biomarkers for early stage lung cancer. The research includes a precancer genome atlas (PCGA) study, and the partners aim to find new therapeutic targets and develop interceptive products. The partners said terms

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE